Treatment of Multiple Sclerosis

1. Front Matter

   Pages i-xviii

   PDF

2. Experimental Therapies for Multiple Sclerosis: Historical Perspective

   • George W. Ellison

   Pages 1-15

3. The Natural History of Multiple Sclerosis

   • Donald E. Goodkin

   Pages 17-45

4. Assessing the Outcome of Experimental Therapies in Multiple Sclerosis Patients

   • Donald Paty, Ernest Willoughby, John Whitaker

   Pages 47-90

5. Design and Statistical Issues Related to Testing Experimental Therapy in Multiple Sclerosis

   • William Weiss, Emanuel M. Stadlan

   Pages 91-122

6. Pathogenesis of Multiple Sclerosis: Relationship to Therapeutic Strategies

   • Richard M. Ransohoff

   Pages 123-133

7. Treatment of Multiple Sclerosis with ACTH and Corticosteroids

   • Lawrence W. Myers

   Pages 135-156

8. Treatment of Multiple Sclerosis with Azathioprine

   • Richard A. C. Hughes

   Pages 157-172

9. Treatment of Multiple Sclerosis with Copolymer I

   • Murray B. Bornstein, Kenneth P. Johnson

   Pages 173-198

10. Treatment of Multiple Sclerosis with Cyclophosphamide

    • Glenn A. Mackin, David M. Dawson, David A. Hafler, Howard L. Weiner

    Pages 199-216

11. Treatment of Multiple Sclerosis with Cyclosporine A

    • Jerry S. Wolinsky

    Pages 217-232

12. Treatment of Multiple Sclerosis with Interferons

    • Lawrence Jacobs, Frederick Munschauer

    Pages 233-250

13. Treatment of Multiple Sclerosis with Plasma Exchange

    • John H. Noseworthy

    Pages 251-266

14. Total Lymphoid Irradiation in Multiple Sclerosis

    • Stuart D. Cook, Corinne Devereux, Raymond Troiano, Christine Rohowsky-Kochan, Amiram Sheffet, Annette Jotkowitz et al.

    Pages 267-279

15. Specific Immunotherapeutic Strategies: Lessons from Myelin Basic Protein-Induced Experimental Allergic Encephalomyelitis

    • Robert B. Bell, Lawrence Steinman

    Pages 281-299

16. Experimental Approaches to Specific Immunotherapy in Multiple Sclerosis

    • David A. Hafler, Staley A. Brod, Howard L. Weiner

    Pages 301-307

17. Back Matter

    Pages 309-313

    PDF

Multiple sclerosis is one of the major current problems in neurol­ ogical practice. It remains incompletely understood, yet is a common cause of chronic disability in developed Western so­ cieties: Patients with the disease have difficulty understanding what has happened to them and become bewildered by the con­ trast between the evidently large body of knowledge concerning the clinical manifestations and course of the disease, and the conflicting views they so often receive from different specialists as to the best current management of their disease. As in so many disorders for which treatment is only partially effective, at best, "alternative" therapies abound. Dr. Rudick and Dr. Goodkin have extensive experience in the day-to-day management of multiple sclerosis at the Mellen Center for Multiple Sclerosis Treatment and Research, attached to the Cleveland Clinic. In this book they have assembled a group of experts from several countries and have provided a comprehensive review of the results of different treatments of the disease. Each treatment is considered in the light of its proposed scientific basis or mode of action, and in relation to ethical and trial design issues. This information deserves to be made widely available. As the treatment of multiple sclerosis enters a new era as a result of the new understanding of the cellular mechanisms of demyelination and the molecular biology of the immune response, this information about current treatments assumes additional importance. The book is of interest to all physicians concerned with the management of patients with the disease.

• Autoimmunity
• Clinical trials
• Multiple Sklerose
• clinical trial
• immunotherapy
• interferon
• multiple sclerosis
• myelin
• research
• steroids

• Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, USA

  Richard A. Rudick, Donald E. Goodkin

Policies and ethics